Celebrex Premedication in Teeth With Symptomatic Irreversible Pulpitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03339544|
Recruitment Status : Not yet recruiting
First Posted : November 13, 2017
Last Update Posted : November 13, 2017
|Condition or disease||Intervention/treatment||Phase|
|Pulpitis||Drug: Celebrex premedication Drug: Placebo||Not Applicable|
Owing to the painful nature of endodotnic treatment in teeth with irreversible pulpits, administration of an analgesic and anti-inflammatory could help to lessen the perception of pain, hence decreasing the patient apprehension.
Previous clinical trials have shown that the use of NSAIDS as a premedication prior to endodontic treatment was effective in reducing the pain and increasing the anesthetic success, since as high as 80% of the patients with pre-operative pain experience pain after endodontic treatment.
In this study, Celebrex (Celecoxib) 200mg will be given to the patients 1 hour before initiation of the treatment, and its effect on reducing the pain will be compared with a placebo.
Celebrex being a selective COX-2 inhibitor, it will spare the physiological tissue prostaglandin production while inhibiting the inflammatory prostaglandin production thus allow for effective analgesia with fewer side effects than Non-Selective NSAIDS (nsNSAIDS).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||46 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Effect of Celebrex Pre-medication on the Intra and Post-treatment Endodontic Pain in Teeth With Symptomatic Irreversible Pulpitis: Double Blind Randomized Clinical Trial|
|Estimated Study Start Date :||December 1, 2017|
|Estimated Primary Completion Date :||December 1, 2018|
|Estimated Study Completion Date :||December 2019|
Experimental: Celebrex premedication
Celebrex is a NSAID with selective COX-2 inhibition properties, is given as an intervention to assess the pain
Drug: Celebrex premedication
celebrex (celecoxib) 200mg is a non-steroidal anti-infalmmatory drug with selective COX-2 inhibition.
Other Name: Celecoxib
Placebo Comparator: Placebo tablets
placebo tablets to compare the efficacy of Celebrex on the intra-operative and post-operative pain accompanying endodontic treatment of teeth with irreversible pulpits
placebo is given as a tablet before initiation of endodontic treatment
- pain intensity (intra-operative pain) [ Time Frame: 1 hour after administration of the drug up to 2 hours till the end of endodontic treatment ]pain intensity during endodontic treatment, measured by Visual Analogue Scale (pain scale)
- alleviation of pain severity [ Time Frame: 24 hours ]severity of pain is measured by Visual Analogue Scale
- number of analgesic tablets taken by the patient after endodontic treatment [ Time Frame: 24 hours ]counting the number of analgesic tablets taken by the patient after the treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03339544
|Contact: Yousra Khaledemail@example.com|
|Contact: Geraldine Ahmedfirstname.lastname@example.org|